Literature DB >> 27136700

The role of cardiac magnetic resonance in assessing the cardiac involvement in Gaucher type 1 patients: morphological and functional evaluations.

Alberto Roghi1, Erika Poggiali, Elena Cassinerio, Patrizia Pedrotti, Marianna Giuditta, Angela Milazzo, Giuseppina Quattrocchi, Maria Domenica Cappellini.   

Abstract

BACKGROUND: Type 1 Gaucher disease (GD1) is the most common lysosomal disorder, characterized by the accumulation of beta-glucocerebroside into the macrophages of several organs. Cardiac involvement is rare and referred to as restrictive cardiomyopathy, pulmonary hypertension, and calcifications of the valves and the aortic arch. AIM: To assess the cardiovascular status by cardiac magnetic resonance, including evaluation of tissue characterization, in GD1 patients.
METHODS: Nine GD1 patients were recruited at the Tertiary Care Centre for Rare Diseases at Ca' Granda Foundation IRCCS Hospital, Milan. The patients' records were available for a mean time of 6 ± 3 years. Medical history of cardiac disease and cardiovascular risk factors were surveyed by direct interview. Patients were scanned with a 1.5 Avanto Siemens using a comprehensive cardiovascular evaluation protocol, including morphologic and functional sequences with gadolinium contrast media, to assess early and late enhancement (late gadolinium enhancement). Echocardiography was performed to study the cardiac morphology and function, including the measurement of pulmonary pressure.
RESULTS: Three patients showed left atrial enlargement, one patient showed moderate aortic stenosis in bicuspid valve with mild aortic dilatation, and one patient showed moderate mitral regurgitation. No evidence of myocardial late gadolinium enhancement was detected after gadolinium contrast media. Seven patients received enzyme replacement therapy for a median of 1 year, and two patients were evaluated at diagnosis.
CONCLUSION: Although cardiac disease in Gaucher disease is considered rare and associated with particular genotypes, we have found two valvular diseases and mild left atrial enlargement in three out of nine patients. Further studies to evaluate the prognostic value of these findings are warranted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27136700     DOI: 10.2459/JCM.0000000000000326

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  5 in total

Review 1.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

Review 2.  Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement.

Authors:  Andrew J Degnan; Victor M Ho-Fung; Rebecca C Ahrens-Nicklas; Christian A Barrera; Suraj D Serai; Dah-Jyuu Wang; Can Ficicioglu
Journal:  Insights Imaging       Date:  2019-07-10

3.  Two Case Reports of Progressive Pulmonary Hypertension with Type-1 Gaucher Disease: Efficient PAH-Specific Therapy and 1-Year Follow-Up.

Authors:  Burcu Yağmur; Sanem Nalbantgil; Meral Kayıkçıoğlu
Journal:  Anatol J Cardiol       Date:  2022-07       Impact factor: 1.475

4.  Cardiac Manifestations in a Group of Romanian Patients with Gaucher Disease Type 1 (a Monocentric Study).

Authors:  Cecilia Lazea; Simona Bucerzan; Camelia Al-Khzouz; Anca Zimmermann; Ștefan Cristian Vesa; Ioana Nașcu; Victoria Creț; Mirela Crișan; Carmen Asăvoaie; Diana Miclea; Paula Grigorescu-Sido
Journal:  Diagnostics (Basel)       Date:  2021-05-29

5.  Cardiopulmonary assessment of patients diagnosed with Gaucher's disease type I.

Authors:  Marija Bjelobrk; Milan Lakocevic; Svetozar Damjanovic; Milan Petakov; Milan Petrovic; Zoran Bosnic; Ross Arena; Dejana Popovic
Journal:  Mol Genet Genomic Med       Date:  2021-07-18       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.